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Detection of anthracycline-induced 
cardiotoxicity: is there light at the end of the 
tunnel?
Cardiac contractile dysfunction is the most serious cardiotoxic
effect of anthracycline therapy and a major limitation for the
use of this effective antineoplastic treatment. The reported
incidence of doxorubicin-induced cardiac dysfunction varies
from 4%, at a cumulative dose of 500–550 mg/m2, to >36% in
patients receiving 600 mg/m2 or more [1]. Interestingly, there
is a non-linear correlation between the incidence of contractile
dysfunction and the cumulative dose of anthracyclines, and
toxicity varies significantly among different anthracyclines.
The prognosis of anthracycline-induced cardiotoxicity is
poor, and possibly even worse than those of ischemic or idio-
pathic dilated cardiomyopathies [2]. In untreated patients,
mortality from anthracycline-induced cardiomyopathy is as
high as 40% over 5 years. However, recent data suggest that
medical therapy may improve the prognosis of patients
dramatically. Furthermore, the onset of anthracycline-induced
heart failure can occur years after the treatment and recent data
from pivotal trials with an antibody against the tyrosine kinase
receptor HER2 (trastuzumab) suggest that anthracycline-
induced cardiotoxicity can be latent for years. Not only
patients treated concomitantly with anthracyclines and trastu-
zumab, but also patients with prior anthracycline treatment,
were at a higher risk of trastuzumab-associated cardiac
dysfunction and heart failure [3]. These observations suggest a
‘cardiac memory’ for prior anthracycline treatment and early
detection of chemotherapy-induced cardiac damage, even if
subclinical, is warranted.
Patients treated with anthracyclines or trastuzumab there-
fore need careful cardiac monitoring. This monitoring should
ideally be highly sensitive and specific, non-invasive, and
available at reasonable cost. Clinical monitoring of patients
based on symptoms and findings of heart failure is not suf-
ficient since time of cardiac contractile dysfunction relative to
anthracycline exposure is highly variable and treatable cardiac
dysfunction frequently precedes the onset of symptoms. So,
what is the best method of monitoring patients for anthra-
cycline-induced cardiac dysfunction?
Right ventricular myocardial biopsy, resting and exercise
echocardiography, and radionuclide ventriculography have
been used to detect early signs of anthracycline-induced cardio-
toxicity. Most of these methods, however, have not been
prospectively evaluated. In this issue of Annals of Oncology,
Jensen et al. [4] report a prospective examination of the left
ventricular function in breast cancer patients treated with epi-
rubicin. They found that cardiotoxicity was closely correlated
with the cumulative dose of epirubicin. However, there was a
great variability of cardiotoxicity among patients and a
dramatic increase in susceptibility in older patients. Using
radionuclide ventriculography they detected a progressive
decrease in cardiac contractile function starting 3 months after
initiation of chemotherapy and 20% of their patients treated
with high-dose epirubicin developed severe dilated cardio-
myopathy within 5 years. The authors conclude that assess-
ment of left ventricular function during or immediately after
chemotherapy is unlikely to predict anthracycline-induced
cardiotoxicity and that serial assessment of left ventricular
function months to years after anthracycline administration is
needed to detect cardiotoxicity.
The results of Jensen et al. [4] are not surprising since it is
known that cardiac dysfunction, irrespective of its etiology, is
a progressive disease. In the past decade, it became clear that
this progression is largely mediated by the activation of neuro-
hormones such as the renin–angiotensin–aldosterone or the
β-adrenergic systems. Therefore, it also comes as no surprise
that treatment with drugs such as ACE-inhibitors or β-receptor
blockers, which inhibit or attenuate the activation of neuro-
hormones, is beneficial in patients with anthracycline-induced
cardiotoxicity. However, the detection of, the frequently
asymptomatic, contractile dysfunction is a prerequisite to
prevent the deleterious natural course of anthracycline-induced
cardiotoxicity.
Serial assessment of cardiac function with radionuclide
ventriculography after anthracycline therapy is elaborate,
expensive and not widely available. Furthermore, radio-
nuclide ventriculography only detects systolic dysfunction and
by that time myocardial damage might have already signifi-
cantly progressed. It would therefore be advantageous to have
markers of early anthracycline-induced myocardial damage.
Again in this issue of the Annals of Oncology, Cardinale et al
[5] report their findings on the use of troponin I for the detec-
tion of chemotherapy-induced cardiotoxicity. These investi-
gators measured plasma troponin I concentration during and
shortly after administration of chemotherapy and assessed left
ventricular contractile function by serial echocardiographic
measurement 1–12 months after the end of treatment. Approxi-
mately 50% of their patients were treated with a chemothera-
peutic regimen containing anthracyclines whereas the rest of
the patients had been treated previously with anthracyclines.
Cardinale et al. [5] found a rise in circulating troponin I in 33%
of their patients, almost 80% of whom were treated with
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epirubicin (200 mg/m2). Furthermore, the investigators
detected a close correlation between maximally elevated
plasma levels of troponin I and the decrease of echocardio-
graphically determined left ventricular ejection fraction.
The troponins, a protein located in the contractile apparatus
of myocytes, have been extensively studied over the past
decade and are sensitive and specific markers for myocardial
injury. In patients with acute coronary syndromes the plasma
levels of troponin correlate well with short-term, as well as
long-term, mortality. However, troponins are only released
into the plasma when myocardial myocytes undergo necrosis.
Therefore, a rise in troponin during and shortly after chemo-
therapy reflects the acute cardiotoxicity of chemotherapeutic
treatment. Whether this rise in troponin levels is correlated
with chronic anthracycline-induced cardiotoxicity, which
typically becomes manifest months to years after chemother-
apy, remains to be seen. Pathophysiological mechanisms
other than cell necrosis, such as oxidative stress induced
changes in contractile protein turnover and mitochondrial
function, leading to myofibrillar disarray and apoptosis might
play a major role in chronic anthracycline-induced cardio-
toxicity. These changes are not likely to be detectable by the
release of tropinin I. Furthermore, the negative predictive
value of troponin for anthracycline-induced chronic cardio-
toxicity has not yet been determined.
In the search for other markers of chemotherapy-induced
cardiac toxicity it is important to understand the pathophysi-
ology of anthracycline-induced cardiotoxicity. Anthracycline-
induced heart failure is a progressive clinical syndrome
characterized by abnormalities of left ventricular function and
neurohormonal activation, which are frequently accompanied
by fluid retention. The most commonly recognized form of
anthracycline-induced heart failure is systolic dysfunction
caused by contractile failure of the myocardium leading to
reduced left ventricular ejection fraction. The ejection fraction
is the proportion of blood that is expelled from the ventricle
with each heart beat, with a normal ejection fraction being
≥50%. If the ejection fraction falls below 50%, the left ven-
tricular pressure at the end of diastole rises, leading to elevated
pressures in the pulmonary vessels and causing pulmonary
congestion. A similar elevation of the left ventricular end
diastolic pressure is the consequence of diastolic dysfunction,
which in anthracycline-induced cardiac dysfunction possibly
precedes systolic dysfunction [6]. Diastolic dysfunction is
characterized by normal systolic function but impaired relax-
ation properties of the ventricle, leading again to an elevated
end diastolic pressure and pulmonary congestion. Therefore,
measuring the end diastolic pressure would be a reliable
marker for the early detection of anthracycline-induced
cardiac dysfunction but presently the only reliable method for
the assessment of this pressure is cardiac catheterization.
A new tool for the diagnosis and assessment of heart failure
is the 32-amino acid polypeptide B-type natriuretic peptide
(BNP). The synthesis of BNP occurs in the ventricles of the
heart and the serum level correlates with the severity of heart
failure and with left (as well as right) ventricular pressures.
Elevated BNP is found both in patients with diastolic dysfunc-
tion and those with systolic dysfunction, and the plasma level
correlates with left ventricular end diastolic pressure [7].
Since the negative predictive value of BNP is as high as 98%,
low BNP plasma levels make ventricular dysfunction highly
unlikely and BNP might therefore be the long awaited tool to
screen for anthracycline-induced cardiotoxicity. Since diastolic
dysfunction in anthracycline-induced cardiotoxicity likely
precedes systolic dysfunction, elevated BNP levels might also
be a more sensitive marker for monitoring cardiac function
after chemotherapy than any other currently used screening
tools. So far, two small studies have evaluated the usefulness
of BNP as a predictor of anthracycline-induced cardiotoxicity
[8, 9]. Both have shown promising results and the findings
suggest that BNP might not only be able to detect overt
anthracycline-induced cardiotoxicity but also subclinical left
ventricular diastolic dysfunction [9]. These preliminary
results need to be confirmed in large-scale prospective trials,
some of which are about to start. It would be a great relief for
oncologists as well as cardiologists if BNP would be the light
at the end of the tunnel in the detection of anthracycline-
induced cardiotoxicity.
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